We believe that topical janus kinase 1 (JAK1) inhibitor therapy for alopecia areata requires the drug to be delivered to the site of the inflammation, deep in the skin at the base (bulb) of the hair follicle. ARQ-255 is an alternative topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. Arcutis currently has formulation and preclinical efforts underway for ARQ-255, which, if successful, will allow ARQ-255 to enter the clinic as potentially the only topical treatment for alopecia areata.
Download our corporate fact sheet.
Download